1	Nasal colonizing vancomycin-resistant and intermediate Staphylococcus aureus among
2	admitted patients
3	Biniyam Kijineh Mengistu ^{1, 2} , Tsegaye Alemayehu ² , Techilo Habtemariam Mengesha ³ , Musa
4	Mohammed Ali ^{2*}
5	¹ Department of Medical Laboratory Science, Wachamo University, Hosana, Ethiopia
6	² School of Medical Laboratory Science, College of Medicine and Health Sciences, Hawassa
7	University, Hawassa, Ethiopia
8	³ Hawassa University Comprehensive Specialized Hospital, Hawassa, Ethiopia
9	*Corresponding author
10	
11	Abstract
12	Background: Staphylococcus aureus colonizing the nasal cavity is a potential source of
13	infections. Vancomycin is a mainstay for treating invasive infections caused by penicillin and
14	methicillin-resistant S. aureus (MRSA). Some reports indicate the emergence of vancomycin-
15	resistant S. aureus (VRSA) making it a high-priority pathogen that needs attention. There is a
16	limited report on the epidemiology of VRSA and vancomycin-intermediate S. aureus (VISA)
17	from the Sidama regional state.
18	Objective: The objective of this study was to determine VRSA and VISA among S. aureus
19	colonizing patients admitted at Hawassa University Comprehensive Specialized Hospital
20	(HUCSH), associated factors, and antimicrobial susceptibility profile.
21	Methods: A hospital-based prospective cross-sectional study was conducted from April to
22	June 2023. Socio-demographic and clinical data were collected using an interviewer-
23	administered questionnaire. Nasal swabs were collected from 378 admitted patients.
24	Identification of S. aureus was made using standard bacteriological methods. VRSA was
25	determined by the Epsilometer test (E-test). The antimicrobial susceptibility profile was
26	determined according to the Kirby-Bauer disk diffusion method. Data was analyzed using
27	SPSS version 22. A p<0.05 was taken as a cut point to determine a statistically significant
28	association.
29	Results: Out of the total 92 <i>S. aureus</i> isolated 12 (13.04%), 27(29.3%), 15(16.3%) were
30	VRSA, VISA, and MRSA respectively. The carriage rate of VRSA and VISA among
31	admitted patients were 12(3.2%) with 95% CI: 1.7%-5.5% and 27(7.14%) with 95% CI:
32	4.8%-10.2% respectively. The overall nasal carriage rate of S. aureus and MRSA was

92(24.3%) with 95% CI: 20.1%–29% and 15(3.97%) with 95% CI: 2.2%–6.5% respectively. Of the VRSA isolates, 11(91.7%) were susceptible to tigecycline. Forty (43.5%) of *S. aureus* were positive for inducible clindamycin resistance. Participants with a history of hospitalization at the intensive care unit were 37 times more likely to be colonized with VRSA (p=0.001). Participants who have domestic animals were 22 times more likely to be colonized with VRSA (p=0.021).

39 Conclusions: This study indicated a high proportion of VRSA and VISA among *S. aureus* 40 isolated from hospitalized patients in the study area. More than 80% of VRSA were 41 susceptible to tigecycline. History of hospitalization at the intensive care unit and having 42 domestic animals at home could increase the odds of VRSA colonization.

Keywords: Nasal Carriage Rate, Vancomycin resistant *Staphylococcus aureus*, Methicillin
resistant *S. aureus*, Admitted patients, Sidama, Ethiopia

45

46 Background

47 Antimicrobial resistance (AMR) is one of the most important public health problems in the 48 world disproportionately affecting low-income countries (1). Worldwide dissemination of 49 drug-resistant bacteria with few developments of antimicrobial agents is a formidable 50 challenge that the physicians of today are facing (1).

Staphylococcus aureus is among potential pathogenic bacteria with diverse virulence factors and the potential to develop resistance to commonly used antimicrobial agents. *S. aureus* are colonizer of the skin and upper respiratory tract without causing diseases. If there are underlying conditions it can cause community and hospital-acquired infections such as soft tissue infections, bacteremia, endocarditis, pneumonia, meningitis, and osteomyelitis (2).

S. aureus is a frequent inhabitant of the human upper respiratory tract and the skin (3);
however, the carriage rate varies based on geographic location, age, gender, and ethnicity (4).
The nasal carriage of *S. aureus* has been identified as a risk factor for community-acquired and nosocomial infections (5).

S. aureus has developed resistance to penicillin and methicillin over time, which makes
infection caused by S. aureus difficult to treat (6). Vancomycin, a glycopeptide antibiotic,
has been used as a last-line antibiotic for treating life-threatening infections caused by
Methicillin-resistant S. aureus (MRSA) (7). This option is being challenged by the emergence

64 and spread of *S. aureus* which are completely resistant to vancomycin or reduced 65 susceptibility to vancomycin (7, 8).

66 S. aureus strains exhibiting reduced susceptibility to vancomycin, vancomycin intermediate-67 resistant S. aureus (VISA), were discovered in the 1990s. S. aureus isolates with complete 68 resistance to vancomycin, vancomycin-resistant S. aureus (VRSA), was first reported in the 69 United States in 2002. The burden of VISA is higher than VRSA; it is associated with 70 persistent infections, vancomycin treatment failure, and poor clinical outcomes (7, 8). VRSA 71 was among the list of antibiotic-resistant microorganisms identified by the World Health 72 Organization (WHO) in 2017 for which new antibiotics should be developed (9). 73 Furthermore, VRSA remained in the 2019 WHO updated list as a high-priority pathogen 74 (10).

75 Infections caused by VRSA have been associated with high morbidity and mortality rates due 76 to the limited availability of effective drugs, particularly in low-income countries. In 77 Ethiopia, the prevalence of drug-resistant bacteria has been increasing from time to time (11). 78 The prevalence of VRSA reported from other parts of Ethiopia (12, 14) is mostly based on 79 the disc diffusion method. Some studies from Ethiopia used E-test and Micro-dilution 80 methods for the determination of VRSA (15, 16). In addition to searching for alternative 81 treatments for infection caused by VRSA, it is important to monitor the epidemiology of 82 VRSA. Considering the scarcity of data in the southern parts of Ethiopia and the disparity in 83 methods used for the detection of VRSA, we primarily envisaged determining the nasal 84 carriage rate of VRSA among admitted patients, its predictors, and antimicrobial 85 susceptibility profile. We also determined the proportion of VISA, MRSA, and ICR S. 86 aureus.

87 Methods


88 Study design and study population

A hospital-based prospective cross-sectional study was conducted among patients admitted to Hawassa University Comprehensive Specialized Hospital (HUCSH) from April to June 2023. The hospital is located in Hawassa city, which is the capital city of Sidama regional state, Ethiopia. HUCSH is a referral hospital that provides health-related services for people coming from the Sidama regional state and other neighboring regional states. It has 284 functional beds and 12 wards such as surgical ward, medical ward, ophthalmology ward,

neurology ward, gynecology ward, orthopedics ward, pediatrics ward, pedi-surgery ward,
oncology ward, adult and neonatal intensive care units, and trauma ward. We have included
six wards for the present study based on the patient flow.

In this study, we included patients who were admitted to the HUCSH during the study period
for treatment. Patients who were critically sick and had nasal bleeding were excluded from
the study. The sample size was determined based on a single sample size estimation formula.
We have considered the prevalence of VRSA (4.1%) which was reported from Debre

- 102 Markos, Ethiopia (17). By assuming a 5% for non-response rate, the sample size was 378.
- 103 A total of 2,222 patients were admitted from September to December. The sample size was
- 104 proportionally allocated to seven wards by multiplying, 378/2222 (0.17), with a number of
- 105 patients admitted at each ward between September to December 2022 (Figure 1). A
- 106 systematic random sampling technique was used to select study participants. The k-value was
- 107 determined based on the total number of patients allocated to each ward. The first participant
- 108 was selected using the lottery method.



109

Figure 1. Total number of patients admitted to selected wards of HUCSH from September to

111 December 2022 and proportional allocation of participant at each ward.

112

Data Collection

A structured questionnaire prepared on kobo-collect version 2023.1.2 (United States) was used to collect socio-demographic and clinical data. The questionnaire was prepared after reviewing similar published articles (5, 12, 13, 19). To ensure consistency, the questionnaire was first prepared in English, translated into Amharic, and then translated back into English. The data was collected using the Amharic version of the questionnaire. The questionnaire was pretested in a population representing 5% (n=19) of the sample size at Adare General Hospital, Hawassa, Ethiopia.

121 The anterior nostrils were swabbed aseptically using sterile cotton soaked in saline and 122 placed in a tube containing normal saline. The swabs were inoculated onto mannitol salt agar 123 (MSA) (Oxoid, Hampshire UK) and incubated at 37°C for 24 hours in an aerobic 124 environment. After 24 hours of incubation, MSA plates were inspected for visible growth of 125 bacteria. In cases where there was no visible growth of bacteria, plates were re-incubated for 126 an additional 24 hours. For bacterial growth with yellow colonies on MSA, Gram staining 127 was performed. Gram-positive cocci bacteria in a cluster on microscopic examination were 128 tested using catalase, coagulase, and modified oxidase test. Bacteria were considered as S. 129 aureus if it appeared yellow on MSA, catalase positive, coagulase-positive and modified 130 oxidase test negative. We used a modified oxidase test to differentiate S. aureus from *Micrococcus* which may appear yellow on MSA and can wrongly be considered as *S. aureus*. 131 132 Confirmed S. aureus isolates were tested for VRSA, MRSA, and antimicrobial susceptibility 133 testing. Before use, the sterility of all culture media used in this study was checked by 134 incubating 5% of each batch of the culture media without inoculation. For performance 135 testing of Gram staining, culture media, biochemical tests, and antibiotics reference strains 136 were used.

137 Detection of vancomycin resistant S. aureus

The pure isolate of *S. aureus* was suspended in a phosphate buffer solution until it matched the McFarland 0.5 standard. The suspension was inoculated over the surface of Muller Hinton Agar (MHA) uniformly using a sterile cotton swab dipped into a suspension. Vancomycin E-test (bioMérieux SA, Marcy-1'Étoile, France) was applied to MHA in which *S. aureus* was inoculated and incubated for 24 hours aerobically at 37°C. The reading was interpreted according to Clinical Laboratory Standard Institute (CLSI) guidelines as susceptible, intermediate, and resistant (18). Minimum inhibitory concentrations of $\leq 2 \mu g/ml$,

145 4–8 μ g/ml, and \geq 16 μ g/ml were interpreted as susceptible (S), intermediate (I), and resistant 146 (R) respectively.

To detect MRSA, *S. aureus* suspension was prepared and inoculated onto MHA as mentioned above; a cefoxitin ($30\mu g$) antibiotic was applied and incubated for 18 hours in ambient air at 35° C. Zone of inhibition <21 mm was interpreted as MRSA. Inducible clindamycin resistance (ICR) was identified using a D-test which involves the application of erythromycin (E-15 µg) and clindamycin (CD-2 µg) discs spaced 15–26 mm on MHA as per CLSI guidelines (18). Flattening of the zone of inhibition adjacent to the erythromycin disc and cloudy growth within the zone of inhibition around clindamycin indicates ICR.

154 Antibiotic susceptibility testing

The disc diffusion method was used to determine the antibiotic susceptibility profile of S. 155 156 aureus as described in CLSI guidelines (18). The suspension of S. aureus was prepared and 157 inoculated onto MHA as described above. The antibiotics used for disc diffusion assays 158 include cefoxitin $(30\mu g)$, erythromycin $(15\mu g)$, trimethoprim-sulfamethoxazole (1.25/23.7,159 5µg), ciprofloxacin (5µg), chloramphenicol (30µg), gentamicin (10µg), clindamycin (2µg), 160 azithromycin (15µg), tigecycline (15µg), aztreonam (30µg), doxycycline (30µg), penicillin G 161 (10 unit). MHA was incubated at 35–37°C for 24 hours. The zones of inhibition were 162 measured using a caliper, and interpreted as susceptible (S), intermediate (I), or resistant (R).

163 Data Analysis and Interpretation

Data was cleaned, transformed, coded, and analyzed using SPSS version 22. Data was presented in frequency and percent. The association between independent and dependent variables was determined using the binary logistic regression model; variables with $p \le 0.25$ in bivariate analysis were included in the multivariable logistic regression model to identify variables that predict VRSA colonization. All independent variables with a $p \le 0.05$ were considered statistically significant.

170 **Results**

171 Socio demographic and clinical characteristics

172 A total of 378 admitted patients at HUCSH were included in the study with a 100% response

173 rate. The majority (n=215; 56.9%) of the study participants were males. The mean age of

study participants was 44.5 with a standard deviation (SD) of 19.2 years. Most of the study

175 participants (n=160; 42.3%) were from Sidama Regional State. More than half of the

- 176 participants were on IV or catheter while 126 (33.3%) reported repeated use of antibiotics
- 177 (Table 1).
- 178 Table 1. Socio-demographic and clinical characteristics of admitted patients at Hawassa
- 179 HUCSH, Hawassa, Ethiopia, April to June 2023 (N=378).

Characteristics	Category	Frequency (%)
Gender	Male	215 (56.9)
	Female	163 (43.1)
	Oromia	157 (41.5)
Region	Sidama	160 (42.3)
	SNNPRS	49 (13)
	Amhara	9 (2.4)
	Addis Ababa	1 (0.3)
	Somali	2 (0.5)
Place of residence	Urban	200 (52.9)
	Rural	178 (47.1)
	Self-employed	265 (70.1)
Occupation	Government	-
	Employee	37 (9.8)
	House-wife	70 (18.5)
	Other employment	6 (1.6)
Educational status	No formal education	131 (34.7)
	1–8	168 (44.4)
	9–12	54 (14.3)
	>12	25 (6.6)
	Married	189 (50)
Marital status	Single	102 (27)
	Divorced	58 (15.3)
	Widowed	29 (7.7)
	Oncology	123 (32.5)
Admitted Ward	Ophthalmology	79 (20.9)
	Surgical	60 (15.9)
	Orthopedics	52 (13.8)
	Medical	40 (10.6)
	Neurology	24 (6.3)
	Yes	111 (29.4)
Recurrent wound	No	267 (70.6)
	Yes	132 (34.9)
Current nasal infection/itching	No	246 (65.1)
History of hospitalization in	Yes	169 (44.7)
the last six months	No	209 (55.3)
	Yes	126 (33.3)
Repeated use of antibiotics	No	252 (66.7)
Use of antibiotics with	Yes	65 (51.6)
physician prescription	No	61 (48.4)
History of ICU hospitalization	Yes	67 (17.7)

	No	311 (82.3)
	Yes	93 (24.6)
Prescience of co-morbidity	No	285 (75.4)
	Yes	229 (60.6)
IV/Catheter in the body	No	149 (39.4)
	Yes	216 (57.1)
Regular hand washing	No	162 (42.9)
	Yes	202 (53.4)
Repeated use of public toilet	No	176 (46.6)
	Yes	214 (56.6)
Domestic animal at home	No	164 (43.4)

180 SNNPRS: South nation nationalities and peoples regional state, ICU: Intensive care unit, IV: Intravenous

181 Others option in occupation section includes; the church/mosque leaders

182 **Prevalence of** *S. aureus*, VRSA, and MRSA

183 Out of the total S. aureus isolated, 12(13.04%) 95% CI: 6.9%–21.7% and 27(29.3%) 95% CI; 20.3%-39.8% were VRSA and VISA. 15(16.3%) 95% CI: 9.4%-25.5% of S. aureus were 184 185 MRSA. Out of 15 MRSA, 3 were vancomycin resistant. Out of the total S. aureus isolated, 186 21 (22.83%) were susceptible to both erythromycin and clindamycin whereas 31(33.7%) 187 were resistant to both erythromycin and clindamycin indicating constitutive resistance 188 (cMLSB). Forty (43.5%) of S. aureus were resistant to erythromycin and susceptible to 189 clindamycin indicating ICR (iMLSB). The prevalence of VRSA, VISA, MRSA, and overall 190 S. aureus colonization rate among admitted patients were 12(3.2%) 95% CI: 1.7%-5.5%, 191 27(7.14%) 95%CI: 4.8%–10.2%, 15(3.97%) 95%CI: 2.2%–6.5%, and 92(24.3%) 95% CI: 192 20.1%–29% respectively.

193 Factors associated with VRSA

194	In bivariate logistic regression analysis, recurrent wound ($p=0.04$, COR=3.69(95%)
195	CI:1.06–12.9)), nasal infection (p=0.024, COR=4.4(95%CI:1.21–15.9)), history of
196	hospitalization (p=0.033, COR=4.5(95% CI: 1.13-17.9)), repeated use of antibiotics (p=0.04,
197	COR=3.93(95%CI:1.08–14.2)), history of hospitalization at ICU (<i>p</i> <0.0001,COR= 31.4(95%
198	CI:6.05–162.7)) and having domestic animal at home (p=0.019,COR=12.16(95%CI:
199	1.49–98.6)) were significantly associated with VRSA colonization. Variables with $p < 0.25$ in
200	the bivariate logistic regression model were included in multivariable logistic analysis.
201	History of hospitalization at ICU (p=0.001, AOR=37.2(95% CI: 4.32-320.8)) and having a
202	domestic animal at home (p=0.021, AOR=22.37(95% CI: 1.59-313.1)) were significantly
203	associated with VRSA colonization in multivariable logistic regression analysis (Table 2).
204	
205	

		Frequency		VRSA				Р-
Variables		(%)	Positive n (%)	Negative n(%)	COR(95% CI)	P-value	AOR (95% CI)	value
	Male	66 (71.7)	9 (13.6)	57 (86.4)	1.21(0.30-4.87)	0.78		
Sex	Female	26 (28.3)	3 (11.5)	23 (88.5)	1			
Place of	Rura	42 (45.7)	5 (11.9)	37 (88.1)	0.83(0.24-2.84)	0.77		
residence	Urban	50 (54.3)	7 (14)	43 (86)	1			
	No formal education	30 (32.6)	5 (16.7)	25 (83.3)	1.2(0.12-12.3)	0.88		
	1-8	45 (48.9)	5 (11.2)	40 (88.8)	0.75(0.074-7.57)	0.81		
Educational	9-12	10 (10.9)	1 (10)	9 (90)	0.67(0.035-12.8)	0.78		
status	>12	7(7.6)	1 (14.3)	6 (85.7)	1			
	Married	49 (53.3)	6 (12.2)	43 (87.8)	0.28(0.064-1.2)	0.089		
	Single	23 (25)	1 (4.3)	22 (95.7)	0.09(0.009-0.94)	0.044		
	Widowed	8 (8.7)	1 (12.5)	7 (87.5)	0.28(0.026-3.19)	0.286		
Marita status	Divorced	12 (13)	4 (33.3)	8 (66.7)	1			
	Oncology	22 (23.9)	7 (31.8)	15 (68.2)	1			
	Ophthalmology	25 (27.2)	2 (8)	23 (92)	0.186(0.03-1.02)	0.053		
	Surgical	10 (10.9)	2 (20)	8 (80)	0.54(0.09-3.21)	0.49		
	Orthopedics	18 (19.6)	1 (5.6)	17 (94.4)	0.13(0.014-1.15)	0.06		
	Medical	12 (13)	-	12 (100)	· · · · · ·	0.99		
Ward	Neurology	5 (5.4)	-	5 (100)		0.99		
	Yes	29 (31.5)	7 (24.1)	22 (75.9)	3.69(1.06-12.9)	0.04	1.98(0.27-14.2)	0.49
Recurrent wound	No	63 (68.5)	5 (7.9)	58 (92.1)	1		1	
Current nasal	Yes	33 (35.9)	8 (24.2)	25 (75.8)	4.4(1.21-15.9)	0.024	0.84(0.08-8.1)	0.884
infection/itching	Νο	59 (64.1)	4 (6.8)	55 (93.2)	1		1	
History of Hospitalization in	Yes	41 (44.6)	9 (21.9)	32 (78.1)	4.5(1.13-17.9)	0.033	1.31(0.18-9.48)	0.78
the last 6-month	No	51 (55.4)	3 (5.8)	48 (94.2)	1		1	

207 Table 2. Factors associated with VRSA carriage among patients admitted at HUCSH, Hawassa, Ethiopia, April to June 2023 (N=92).

Repeated use of	Yes	35 (38)	8 (22.9)	27 (77.1)	3.93(1.08-14.2)	0.04	0.99(0.096-10.26)	0.995
Antibiotics	No	57 (62)	4 (7)	53 (93)	1		1	
Use of antibiotics with physician's	Yes	26 (74.3)	5 (19.2)	21 (80.8)	1			
prescription	No	9 (25.7)	3 (33.3)	6 (66.7)	2.1(0.38-11.4)	0.39		
History of ICU	Yes	21 (22.8)	10(47.6)	11 (52.4)	31.4(6.05-162.7)	0.00004	37.2(4.32-320.8)**	0.001
Hospitalization	No	71 (77.2)	2 (2.8)	69 (97.2)	1		1	
Prescience of any	Yes	20 (21.7)	4 (20)	16 (80)	2(0.53-7.48)	0.30		
co-morbidity	No	72 (78.3)	8 (11.1)	64 (88.9)	1			
V/Catheter in	Yes	57 (62)	9 (15.8)	48 (84.2)	2(0.5-7.96)	0.32		
the body	No	35 (38)	3 (8.6)	32 (91.4)	1			
Regular hand	Yes	56 (60.9)	8 (14.3)	48 (85.7)	1.33(0.37-4.8)	0.66		
washing	No	36 (39.1)	4 (11.1)	32 (88.9)	1			
Repeated use of	Yes	58 (63)	9 (15.5)	49 (84.5)	1.89(0.47-7.56)	0.36		
public toilet	No	34 (37)	3 (8.8)	31 (91.2)	1			
Domestic anima	Yes	49 (53.3)	11 (22.4)	38(77.6)	12.16(1.49-98.6)	0.019	22.37(1.59-313.1)*	0.021
in home	No	43 (46.7)	1 (2.3)	42 (97.7)	1		1	

208 VRSA: vancomycin resistant S. aureus, CI: Confidence interval, OR: Odds ratio, AOR: Adjusted odds ratio, ICU: Intensive care unit, AOR: Adjusted odds ratio, ICU: Intensive

209 care unit, COR: Crude odd ratio, AOR: Adjusted odd ratio

210

211

212 In bivariate analysis gender (p=0.001, COR=2.3 (95%CI:1.38–3.8)), repeated use of 213 antibiotics with physician's prescription (p=0.002, COR=0.26(95%CI:0.11-0.62)), and 214 repeated use of public toilet (p=0.035, COR=1.68(95% CI:1.04-2.73)) were significantly 215 associated with overall S. aureus colonization rate while in multivariable analysis gender (p=0.008, AOR=3.67(95%CI:1.4–9.6)), repeated use of antibiotics with physician's 216 217 prescription (p=0.009, AOR=0.28(95% CI: 0.11–0.73)) and history of hospitalization at ICU 218 (p=0.023, AOR=3.34(95% CI: 1.2–9.46)) were significantly associated with overall S. aureus 219 colonization rate (Supplement table 1).

In bivariate logistic analysis, history of ICU hospitalization (p = 0.004, COR = 5.63(95% CI:

221 1.73-18.2)) showed significant association while in multivariate analysis, gender (p = 0.018,

AOR = 0.16(95% CI: 0.035-0.73)) and history of ICU hospitalization (p = 0.008, AOR =

223 8.06(95% CI: 1.72-37.6)) were significantly associated with MRSA colonization

224 (Supplement table 2).

225 Antimicrobial susceptibility profile of VRSA

Out of the total *S. aureus* tested, 92(100%), 76(82.6%), 68(73.9%), and 66(71.7%) were resistant to aztreonam, penicillin G, sulfamethoxazole-trimethoprim (SXT), and azithromycin respectively on the other hand 88(95.7%), 82(89.1%), 77(83.7%) and 71(77.2%) of *S. aureus* were susceptible to tigecycline, doxycycline, cefoxitin, and chloramphenicol respectively (Table 3).

Out of the total VRSA, 12(100%), 11(91.7%), 9(75%), and 7(58.3%) were resistant to aztreonam, azithromycin, clindamycin, and gentamicin respectively while 11(91.75%), 10(83.3%), 9(75%), and 7(58.3%) VRSA were susceptible to tigecycline, doxycycline, cefoxitin, and gentamicin respectively (Table 3). A high proportion of vancomycin susceptible *S. aureus* was positive for inducible clindamycin resistance while the lowest inducible clindamycin resistance was observed among VRSA (Fig 2).

237 Table 3. Antimicrobial susceptibility profile of *S. aureus* and VRSA recovered from patients

	S	5. <i>aureus</i> n=92			VRSA n=:	12
Anti microbials	S, n (%)	l, n (%)	R, n (%)	S, n (%)	l, n (%)	R, n (%)
AZM	23 (25)	3 (3.3)	66 (71.7)	1 (8.3)	0	11 (91.7)
CD	68 (73.9)	1 (1.1)	23 (25)	5 (41.7)	0	7 (58.3)
TGC	88 (95.7)	NR	4 (4.3)	11 (91.75)	NR	1 (8.3)
AZT	0	0	92 (100)	0	0	12 (100)


admitted at HUCSH, Hawassa, Ethiopia. April to June 2023.

CN	56 (60.9)	1 (1.1)	35 (38)	7 (58.3)	1 (8.3)	4 (33.3)	
CIP	47 (51.1)	12 (13)	33 (35.9)	6 (50)	3 (25)	3 (25)	
ERY	21 (22.8)	7 (7.6)	64 (69.6)	1 (8.3)	2 (16.7)	9 (75)	
DOX	82 (89.1)	4 (4.3)	6 (6.5)	10 (83.3)	1 (8.3)	1 (8.3)	
С	71 (77.2)	15 (16.3)	6 (6.5)	6 (50)	3 (25)	3 (25)	
PEN G	16 (17.4)	NR	76 (82.6)	6 (50)	NR	6 (50)	
SXT	24 (26.1)	0	68 (73.9)	1 (8.3)	0	11 (91.7)	
FOX	77 (83.7)	NR	15 (16.3)	9 (75)	NR	3 (25)	

239 VRSA: Vancomycin resistant S. aureus, S: Susceptible, I: Intermediate, R: Resistant, AZM: Azithromycin, CD:

240 Clindamycin, TGC: Tigecycline, AZT: Aztreonam, CN: Gentamicin, CIP: Ciprofloxacin, ERY: Erythromycin, DOX:

242 NR: Not recommended by CLSI



243

244 Figure 2. Clindamycin resistance observed across S. aureus, VRSA and MRSA isolated from

admitted patients at HUCSH, Hawassa, Ethiopia April 05 to June 24 2023

246 VSSA: Vancomycin susceptible S. aureus VISA: Vancomycin intermediate S. aureus, VRSA: Vancomycin resistant S. aureus, S-ERY-CD:

247 Susceptible to both Erythromycin and clindamycin, cMLS_B: constitutive resistance (Resistance to both Erythromycin and Clindamycin),

248 iMLS : inducible resistance to clindamycin, MRSA: Methicillin resistant S. aureus, MSSA: Methicillin susceptible S. aureus

249 **Discussion**

Infections caused by VRSA are public health concerns that require attention from international and national health sectors. Treatment options for VRSA infections are limited. Assessing the epidemiology of VRSA will provide valuable insights to help combat its spread within the community. So far, a few studies in Ethiopia have identified VRSA using the minimum inhibitory concentration method.

The present study found the proportion of VRSA among *S. aureus* isolates to be 13.04%. This is consistent with studies conducted in Eritrea (15.9%) (19), Pakistan (11-15%) (20),

²⁴¹ Doxycycline, C: Chloramphenicol,, PEN G: Penicillin G, SXT:- Sulfamethoxazole- trimethoprim , FOX: Cefoxitin,

Egypt (13.8%) (21), Ethiopia (14-15%) (6, 16, 17, 22), and Indonesia (11%) (23). However,
the VRSA prevalence in this study was higher than many other studies in Addis Ababa,
Ethiopia (4-7%) (14, 15, 24), the global pooled estimate (6%) (25), Yemen (5.12%) (26), and
Egypt (4.5%) (27). Conversely, studies from Nigeria (44.5%) (3), Bangladesh (27.6%) (26),
and Egypt (24%) (29) reported a higher VRSA prevalence than the current study. The lowest
VRSA rate (4.1%) in Ethiopia was reported from Jigjiga (14).

These variations could be attributed to differences in the study population, specimen collection site, laboratory method, study period, and antibiotic usage practices. The current study did not determine the origin of VRSA in the patients, who were admitted for various medical conditions. VRSA could have been acquired in the community before admission or during hospitalization. Further investigation using molecular epidemiology is needed to elucidate the source of VRSA in these patients.

269 The study found that participants with a history of ICU hospitalization were more likely to be 270 colonized with VRSA (p=0.001). Similar findings have been reported in previous studies by 271 Wu et al. (25) and Shariati et al. (30). This could be attributed to the misuse of antimicrobial 272 agents and the use of contaminated medical devices in hospital settings during patient 273 management. Additionally, participants who had domestic animals at home were also more 274 likely to be colonized with VRSA compared to those without domestic animals. This 275 observation aligns with findings from other studies conducted in Ethiopia (17, 31). This may 276 suggest that domestic animals could be a potential source of VRSA; however, the current 277 study was not designed to definitively determine the source of VRSA infection.

The study found that all VRSA isolates were resistant to aztreonam, which is consistent with findings from a study conducted in Hyderabad (32). Additionally, over 25% of the isolates were resistant to azithromycin and sulfamethoxazole-trimethoprim, which is lower than the resistance rates reported in a study from Egypt (21). Conversely, only one isolate was resistant to tigecycline, a similar observation to a study in Pakistan (20).

The nasal carriage rate of *S. aureus* has been extensively studied, and various colonization rates have been reported across different regions and study populations (13, 33, 34, 43). The overall nasal carriage rate of *S. aureus* (24.3%) found in the present study is comparable to rates reported from Ethiopia (28.8%) (13), China (24.7%) (33), and Iran (21.3%) (43). However, it is lower than the rates observed in studies conducted in Iraq (39.4%) (34) and

other parts of Ethiopia (32%-39%) (16, 35). Notably, the nasal carriage rate in this study was
higher than rates reported in other regions of Ethiopia (13%-16%) (36, 37).

These variations in the nasal carriage of *S. aureus* across different regions of Ethiopia suggest the existence of other factors that may contribute to different levels of colonization rates. The differences in the isolation rates of *S. aureus* among studies could be attributed to variations in clinical characteristics, study settings, socio-demographic factors, and individual behaviors.

295 The study found that male participants were 3.67 times more likely to be colonized with S. 296 *aureus*, which contradicts the findings of other studies conducted in Jimma, Ethiopia (38). 297 This discrepancy could be attributed to behavioral differences between males and females 298 residing in various geographic locations within Ethiopia. Interestingly, study participants who 299 did not use antibiotics without a physician's prescription were 72% less likely to be colonized 300 with S. aureus. Additionally, participants with a history of ICU hospitalization were 3.34 301 times more likely to be colonized with S. aureus, a finding that aligns with the report by 302 Humphreys et al. (39).

Among the 92 *S. aureus* isolates in the current study, 16.3% were resistant to cefoxitin, which is lower than the resistance rate reported in a study from Nigeria (40). However, 69.6% and 25% of the *S. aureus* isolates were resistant to erythromycin and clindamycin, respectively, which is lower than the resistance rates observed in a study conducted in Iran (41).

The magnitude of MRSA detected in the current study (16.3%) is consistent with reports from various parts of the world (11.2%-17.3%) (12, 15, 36, 43). However, it is lower than the MRSA rates reported in studies from Pakistan (76%) (44), Iran (74.2%) (45), Yemen (65%) (26), different regions of Ethiopia (30%-45%) (16, 17, 35, 46), Sudan (41%) (47), and Nepal

311 (31.2%) (48).

Interestingly, male participants were about 84% less likely to be colonized with MRSA, which aligns with findings from other parts of Ethiopia (17, 39). Similar to the patterns observed for *S. aureus* and VRSA colonization, participants with a history of ICU hospitalization were about 8 times more likely to be colonized with MRSA compared to those without such a history.

317

318

319 Limitation of the study

320 The present study did not employ the broth dilution method for the determination of VRSA.

As a result, this work should be interpreted while considering the inherent limitations associated with the use of the E-test technique for VRSA detection.

323 Conclusions

The study found that the proportion of vancomycin-resistant and vancomycin-intermediate Staphylococcus aureus (VRSA and VISA) was relatively high in the study area. Importantly, a history of hospitalization in the Intensive Care Unit (ICU) and having domestic animals at home were significantly associated with VRSA colonization. Further analysis revealed that most of the VRSA isolates were resistant to aztreonam, azithromycin, clindamycin, and gentamicin. In contrast, more than 80% of the VRSA isolates were susceptible to tigecycline and doxycycline.

331 Abbreviations

- 332 VRSA: Vancomycin-resistant S. aureus, VISA: Vancomycin intermediate S. aureus,
- HUCSH: Hawassa University Comprehensive Specialized Hospital, E-test: Epsilometer test,
- MRSA: Methicillin resistant *S. aureus*, MHA: Muller Hinton Agar, CLSI: Clinical
 Laboratory Standard Institute, ICU: Intensive care unit

336 Acknowledgments

We would like to acknowledge nurses and laboratory scientist working at selected wards of HUCSH and teaching Microbiology laboratory respectively. We also acknowledge study participants for their willingness to take part in the study.

340 **Declaration**

341 Ethical approval and consent to participate

Ethical approval was obtained from the institutional review board (IRB) of Hawassa University College of Medicine and Health Sciences with Ref No of IRB/171/15. Written informed consent was obtained from adults participants. For minors, both consent and assent was obtained. All methods were performed in accordance with the relevant guidelines and regulations.

347 Funding

- 348 This study was partly supported by Hawassa University. The supporter does not have any
- 349 role in designing and data collection.

350 Availability of data and materials

351 The data set used can be obtained from corresponding author.

352 Authors' contributions

353 BKM: Proposal development, laboratory work, data analysis, and drafting the original

- 354 manuscript **TA:** supervision of the study, data analysis, and review of the manuscript **THM:**
- supervision of the laboratory work, and review of the manuscript MMA: proposed the study,
- supervision of laboratory work, data analysis and manuscript preparation

357 Consent for publication

358 Not applicable

359 Competing interests

360 The authors declare that they have no competing interests.

361 **References**

- Melese A, Genet C, Andualem T. Prevalence of Vancomycin resistant enterococci
 (VRE) in Ethiopia: a systematic review and meta-analysis. BMC infectious diseases.
 2020 Dec; 20 (1):1-2.
- Zheng X, Fang R, Wang C, Tian X, Lin J, Zeng W, *et al.* Resistance profiles and
 biological characteristics of rifampicin-resistant Staphylococcus aureus small-colony
 variants. Infection and Drug Resistance. 2021 Apr 21:1527-36.
- Olufunmiso O, Tolulope I, Roger C. Multidrug and vancomycin resistance among
 clinical isolates of Staphylococcus aureus from different teaching hospitals in Nigeria.
 African health sciences. 2017 Sep 18; 17 (3):797-807.
- 4. Sollid JU, Furberg AS, Hanssen AM, Johannessen M. Staphylococcus aureus:
 determinants of human carriage. Infection, genetics and evolution. 2014 Jan 1; 21:
 531-41.
- 5. Legese H, Kahsay AG, Kahsay A, Araya T, Adhanom G, Muthupandian S, *et al.*Nasal carriage, risk factors and antimicrobial susceptibility pattern of methicillin
 resistant Staphylococcus aureus among healthcare workers in Adigrat and Wukro

377	hospitals, Tigray, Northern Ethiopia. BMC research notes. 2018 Dec; 11 (1):1-6.
378	6. Belete MA, Gedefie A, Alemayehu E, Debash H, Mohammed O, Gebretsadik D, et al.
379	The prevalence of vancomycin-resistant Staphylococcus aureus in Ethiopia: a
380	systematic review and meta-analysis. Antimicrobial Resistance & Infection Control.
381	2023 Aug 30; 12 (1):86.
382	7. McGuinness WA, Malachowa N, DeLeo FR. Focus: infectious diseases: vancomycin
383	resistance in Staphylococcus aureus. The Yale journal of biology and medicine. 2017
384	Jun; 90 (2):269.
385	8. Islam F, Shohag S, Uddin MJ, Islam MR, Nafady MH, Akter A. et al. Exploring the
386	journey of zinc oxide nanoparticles (ZnO-NPs) toward biomedical applications.
387	Materials. 2022 Mar 15; 15 (6):2160.
388	9. Tacconelli E, Magrini N, Kahlmeter G, Singh N. Global priority list of antibiotic-
389	resistant bacteria to guide research. Discovery and Development of New Antibiotics.
390	2017:1-7.
391	10. World Health Organization. 2019 Antibacterial agents in clinical development: an
392	analysis of the antibacterial clinical development pipeline. Geneva: World Health
393	Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.
394	11. Berhe DF, Beyene GT, Seyoum B, Gebre M, Haile K, Tsegaye M, et al. Prevalence
395	of antimicrobial resistance and its clinical implications in Ethiopia: a systematic
396	review. Antimicrobial Resistance & Infection Control. 2021 Dec; 10:1-4.
397	12. Manilal A, Shewangizaw M, Mama M, Gezmu T, Merdekios B. Methicillin-resistant
398	Staphylococcus aureus colonization in HIV patients of Arba Minch province,
399	Ethiopia: carriage rates, antibiotic resistance, and biofilm formation. Acta
400	microbiologica et immunologica Hungarica. 2019 Dec; 66(4):469-83.
401	13. Shibabaw A, Abebe T, Mihret A. Antimicrobial susceptibility pattern of nasal
402	Staphylococcus aureus among Dessie Referral Hospital health care workers, Dessie,
403	Northeast Ethiopia. International Journal of Infectious Diseases. 2014 Aug 1; 25: 22-
404	5.
405	14. Abebe T, Teklemariam Z, Shume T, Mekuria S, Urgesa K, Weldegebreal F. Bacterial
406	Profile of External Ocular Infections, Its Associated Factors, and Antimicrobial
407	Susceptibility Pattern among Patients Attending Karamara Hospital, Jigjiga, Eastern
408	Ethiopia. International Journal of Microbiology. 2023 Mar 10; 2023.
409	15. Dilnessa T, Bitew A. Prevalence and antimicrobial susceptibility pattern of methicillin
410	resistant Staphylococcus aureus isolated from clinical samples at Yekatit 12 Hospital

411	Medical College, Addis Ababa, Ethiopia. BMC infectious diseases. 2016 Dec; 16: 1-
412	9.
413	16. Kejela T, Dekosa F. High prevalence of MRSA and VRSA among inpatients of Mettu
414	Karl Referral Hospital, Southwest Ethiopia. Tropical Medicine & International
415	Health. 2022 Aug; 27(8):735-41.
416	17. Tefera S, Awoke T, Mekonnen D. Methicillin and vancomycin resistant
417	Staphylococcus aureus and associated factors from surgical ward inpatients at Debre
418	Markos Referral Hospital, Northwest Ethiopia. Infection and Drug Resistance. 2021
419	Aug 10:3053-62.
420	18. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial
421	susceptibility testing. CLSI supplement M100. 2022 Jan 18:106-12.
422	19. Garoy EY, Gebreab YB, Achila OO, Tekeste DG, Kesete R, Ghirmay R, et al.
423	Methicillin-resistant Staphylococcus aureus (MRSA): prevalence and antimicrobial
424	sensitivity pattern among patients-a multicenter study in Asmara, Eritrea. Canadian
425	Journal of Infectious Diseases and Medical Microbiology. 2019 Oct;2019.
426	20. Saeed A, Ahsan F, Nawaz M, Iqbal K, Rehman KU, Ijaz T. Incidence of vancomycin
427	resistant phenotype of the methicillin resistant Staphylococcus aureus isolated from a
428	tertiary care hospital in Lahore. Antibiotics. 2019 Dec 18;9(1):3.
429	21. ElSayed N, Ashour M, Amine AE. Vancomycin resistance among Staphylococcus
430	aureus isolates in a rural setting, Egypt. Germs. 2018 Sep;8(3):134.
431	22. Deyno S, Fekadu S, Astatkie A. Resistance of Staphylococcus aureus to antimicrobial
432	agents in Ethiopia: a meta-analysis. Antimicrobial Resistance & Infection Control.
433	2017 Dec;6(1):1-5.
434	23. Ahmad F, Sennang N, Rusli B. Vancomycin resistant Staphylococcus aureus in Dr.
435	Wahidin Sudirohusodo Hospital Makassar. Indonesian Journal of Clinical Pathology
436	and Medical Laboratory. 2019 Apr 13; 25 (2):194-8.
437	24. Alebachew T, Yismaw G, Derabe A, Sisay Z. Staphylococcus aureus burn wound
438	infection among patients attending Yekatit 12 hospital burn unit, Addis Ababa,
439	Ethiopia. Ethiopian journal of health sciences. 2012; 22(3).
440	25. Wu Q, Sabokroo N, Wang Y, Hashemian M, Karamollahi S, Kouhsari E. Systematic
441	review and meta-analysis of the epidemiology of vancomycin-resistance
442	Staphylococcus aureus isolates. Antimicrobial Resistance & Infection Control. 2021
443	Dec; 10: 1-3.
444	26. Abdelmonem MO. Nasal carriage of Staphylococcus aureus among healthcare

workers in althawra hospital, Taiz city, Republic of Yemen. Australian Journal of
Basic and Applied Sciences. 2012;6(7):417-24.

- 27. Shady AH, El-Essawy AK, Salama MS, El-Ayesh AM. Detection and molecular
 characterization of vancomycin resistant Staphylococcus aureus from clinical isolates.
 African Journal of Biotechnology. 2012; 11(99):16494-503.
- 450 28. Hasan R, Acharjee M, Noor R. Prevalence of vancomycin resistant Staphylococcus
 451 aureus (VRSA) in methicillin resistant S. aureus (MRSA) strains isolated from burn
 452 wound infections. Tzu Chi Medical Journal. 2016 Jun 1; 28(2):49-53.
- 453 29. Salah NM, Saafan AE, Salem EH, El Rabey HA, Alsieni MA, Alatawi Fa *et al.*454 Inhibition of the vancomycin resistance in Staphylococcus aureus in Egypt using
 455 silver nanoparticles. BioMed Research International. 2022 Apr 30;2022.
- 30. Shariati A, Dadashi M, Moghadam MT, van Belkum A, Yaslianifard S, DarbanSarokhalil D. Global prevalence and distribution of vancomycin resistant,
 vancomycin intermediate and heterogeneously vancomycin intermediate *Staphylococcus aureus* clinical isolates: a systematic review and meta-analysis.
 Scientific reports. 2020 Jul 29;10(1):12689.
- 31. Beyene T, Hayishe H, Gizaw F, Beyi AF, Abunna F, Mammo B, Ayana D, *et al.*Prevalence and antimicrobial resistance profile of Staphylococcus in dairy farms,
 abattoir and humans in Addis Ababa, Ethiopia. BMC research notes. 2017 Dec; 10
 (1):1-9.
- 32. Thati V, Shivannavar CT, Gaddad SM. Vancomycin resistance among methicillin
 resistant *Staphylococcus aureus* isolates from intensive care units of tertiary care
 hospitals in Hyderabad. The Indian journal of medical research. 2011 Nov;134
 (5):704.
- 33. Chen BJ, Xie XY, Ni LJ, Dai XL, Lu Y, Wu XQ, *et al.* Factors associated with
 Staphylococcus aureus nasal carriage and molecular characteristics among the general
 population at a Medical College Campus in Guangzhou, South China. Annals of
 clinical microbiology and antimicrobials. 2017 Dec; 16: 1-0.
- 34. Rasheed NA, Hussein NR. Prevalence of Nasal Carriage Rate and Antimicrobial
 Susceptibility Testing of *Staphylococcus aureus* Strains Isolated from Syrian Students
 in Kurdistan, Iraq. Middle East Journal of Rehabilitation and Health Studies. 2020 Jul
 31; 7(3).
- 477 35. Eticha T, Tamire T, Gelgelu TB. Antibiotic susceptibility pattern of coagulase
 478 positive *Staphylococcus aureus* isolated from patients admitted at Tikur Anbessa

479	specialized Hospital, Addis Ababa. Health Science Journal. 2022; 16 (2):1-5.
480	36. Wolde W, Mitiku H, Sarkar R, Shume T. Nasal Carriage Rate of <i>Staphylococcus</i>
481	<i>aureus</i> , its associated factors, and antimicrobial susceptibility pattern among health
482	care workers in public hospitals, Harar, Eastern Ethiopia. Infection and Drug
483	Resistance. 2023 Dec 31:3477-86.
484	37. Gebremeskel FT, Alemayehu T, Ali MM. Methicillin-resistant Staphylococcus aureus
485	antibiotic susceptibility profile and associated factors among hospitalized patients at
485	Hawassa University Comprehensive Specialized Hospital, Ethiopia. IJID Regions.
	2022 Jun 1; 3: 129-34.
487	
488	38. Kejela T, Bacha K. Prevalence and antibiotic susceptibility pattern of methicillin-
489	resistant <i>Staphylococcus aureus</i> (MRSA) among primary school children and
490	prisoners in Jimma Town, Southwest Ethiopia. Annals of clinical microbiology and
491	antimicrobials. 2013 Jan; 12: 1-1.
492	39. Humphreys H, Fitzpatick F, Harvey BJ. Gender differences in rates of carriage and
493	bloodstream infection caused by methicillin-resistant Staphylococcus aureus: are they
494	real, do they matter and why? Clinical Infectious Diseases. 2015 Dec 1; 61 (11):1708-
495	14.
496	40. Mamman GP, Angulu CN, Musa G, Angulu S. Identification and antibiotic
497	susceptibility profile of methicillin and erythromycin resistant genes in clinical and
498	environmental strains of Staphylococcus aureus in Minna Nigeria. Bayero Journal of
499	Pure and Applied Sciences. 2022 Dec 9; 15 (1):195-201.
500	41. Zamanian MH, Shirvani M, Janbakhsh A, Sayad B, Vaziri S, Afshar ZM et al.,
501	Antibiotic Resistance in Staphylococcus aureus in patients Hospitalized in Imam Reza
502	Hospital of Kermanshah, Iran (2016-2018). Journal of Kermanshah University of
503	Medical Sciences. 2021 Dec 31; 25(4).
504	42. Hosain Zadegan H, Menati S. The prevalence of methicillin and vancomycin resistant
505	Staphylococcus aureus nasal carriage in large teaching hospital personnel. Afr J
506	Microbiol Res. 2011 Oct 16; 5(22):3716-9.
507	43. Hasanpour AH, Sepidarkish M, Mollalo A, Ardekani A, Almukhtar M, Mechaal A, et
508	al. The global prevalence of methicillin-resistant Staphylococcus aureus colonization
509	in residents of elderly care canters: a systematic review and meta-analysis.
510	Antimicrobial Resistance & Infection Control. 2023 Jan 29; 12(1):4.
511	44. Saeed A, Ahsan F, Nawaz M, Iqbal K, Rehman KU, Ijaz T. Incidence of vancomycin
512	resistant phenotype of the methicillin resistant Staphylococcus aureus isolated from a
	21

513	tertiary care hospital in Lahore. Antibiotics. 2019 Dec 18; 9(1):3.
514	45. Ghasemian R, Najafi N, Makhlough A, Khademlou M. Frequency of nasal carriage of
515	Staphylococcus aureus and its antimicrobial resistance pattern in patients on
516	haemodialysis. 218-221.
517	46. Shibabaw A, Abebe T, Mihret A. Antimicrobial susceptibility pattern of nasal
518	Staphylococcus aureus among Dessie Referral Hospital health care workers, Dessie,
519	Northeast Ethiopia. International Journal of Infectious Diseases. 2014 Aug 1; 25: 22-
520	5.
521	47. Osman MM, Osman MM, Mohamed NA, Osman SM, Magzoub M, El-Sanousi SM.
522	Investigation on vancomycin resistance (VRSA) among methicillin resistant S. aureus
523	(MRSA) in Khartoum State, Sudan. Am J Microbiol Res. 2016 Apr 13; 4(2):56-60.
524	48. Khanal LK, Sah AK, Adhikari RP, Khadka S, Sapkota J, Rai SK. Prevalence and
525	molecular characterization of methicillin resistant Staphylococcus aureus (MRSA)
526	and vancomycin resistant Staphylococcus aureus (VRSA) in a tertiary care hospital.
527	Nepal Medical College Journal. 2023 Mar 21; 25(1):32-7.